Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

August 9, 2007

VEGF trap

This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Donald Fleming, MD, Division Head of Hematology and OncologyDonald Fleming, MD
Division Head of Hematology and Oncology, Davis Health System, Inc.
Implications: Vegf trap useful in wet MD Vegf trap will be a proft maker for this indication Vegf trap is also a contender in cancer therapy

Analysis: Basically the Vegf trap ligand to block VEGF receptor looks promising in wet MD, but we all realize this based on the impressive results with Avastin. Be awrae that these drugs are marketed and chrged according to how much will be used and If a company charges a profitable amont for MD it would be prohibitive in the cost for cancer uses just as we have seen with the avastin contraversy. I feel the drug does have promise just as the other VEGF inhibitor, avastin and yet may have more affintiy to block.

Other Analyses of the Same Source Article:
VEGF Trap (RGN, BAY) may give Lucentis (DNA) some competition in the AMD Market.
August 9, 2007, Author: GLG Expert Contributor
VEGF Trap Makes Progress for Wet AMD
August 8, 2007, Author: GLG Expert Contributor

Report a Concern

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-09-05T05:45:18.073